Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.

PLoS One · 2012 · PMC3256138 · PMID 22247763

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

It is worth noting also that compared to these mouse models, MRL/lpr mice develop a very strong lupus disease and therefore that any improvement of their clinical and biological signs is highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.